Your browser is no longer supported. Please, upgrade your browser.
Settings
DVAX [NASD]
Dynavax Technologies Corporation
Index- P/E- EPS (ttm)-0.62 Insider Own0.30% Shs Outstand112.03M Perf Week0.67%
Market Cap1.04B Forward P/E16.73 EPS next Y0.54 Insider Trans-16.00% Shs Float105.57M Perf Month16.08%
Income-61.80M PEG- EPS next Q-0.05 Inst Own74.20% Short Float16.73% Perf Quarter-11.56%
Sales119.00M P/S8.72 EPS this Y65.50% Inst Trans0.38% Short Ratio6.84 Perf Half Y76.88%
Book/sh0.89 P/B10.06 EPS next Y-1.47% ROA-16.20% Target Price- Perf Year34.49%
Cash/sh2.01 P/C4.46 EPS next 5Y- ROE-86.40% 52W Range3.58 - 12.44 Perf YTD101.12%
Dividend- P/FCF- EPS past 5Y25.50% ROI-28.70% 52W High-26.49% Beta1.21
Dividend %- Quick Ratio3.30 Sales past 5Y63.00% Gross Margin71.50% 52W Low155.45% ATR0.40
Employees245 Current Ratio3.90 Sales Q/Q664.20% Oper. Margin-17.20% RSI (14)55.98 Volatility4.87% 4.56%
OptionableYes Debt/Eq1.80 EPS Q/Q105.30% Profit Margin-51.90% Rel Volume0.78 Prev Close8.95
ShortableNo LT Debt/Eq1.80 EarningsMay 06 AMC Payout- Avg Volume2.58M Price9.15
Recom1.70 SMA204.90% SMA502.47% SMA20030.91% Volume496,526 Change2.18%
Aug-07-20Reiterated H.C. Wainwright Buy $14 → $12
Aug-03-20Reiterated H.C. Wainwright Buy $12 → $14
Jun-15-20Initiated Evercore ISI Outperform $14
Oct-18-19Initiated H.C. Wainwright Buy $13
Jul-11-19Upgrade Cantor Fitzgerald Neutral → Overweight $20
Feb-27-19Reiterated Cantor Fitzgerald Overweight $32 → $28
May-10-18Upgrade JP Morgan Neutral → Overweight
Mar-08-18Reiterated Cantor Fitzgerald Overweight $25 → $27
Feb-14-18Downgrade JP Morgan Overweight → Neutral
Sep-25-17Reiterated RBC Capital Mkts Outperform $26 → $28
Sep-15-17Initiated Cantor Fitzgerald Overweight $24
Jul-31-17Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $26
Jul-31-17Upgrade JP Morgan Neutral → Overweight
May-09-17Reiterated RBC Capital Mkts Sector Perform $6 → $7
Apr-28-16Downgrade RBC Capital Mkts Outperform → Sector Perform $48 → $17
Apr-27-16Downgrade JP Morgan Overweight → Neutral
Nov-30-15Initiated RBC Capital Mkts Outperform $48
Nov-25-13Upgrade MLV & Co Hold → Buy $1.50 → $5
Feb-25-13Downgrade MLV & Co Buy → Hold
Nov-16-12Reiterated MLV & Co Buy $10 → $7.50
Jun-15-21 03:04PM  
11:50AM  
Jun-14-21 03:06AM  
Jun-09-21 04:05PM  
Jun-03-21 03:32PM  
May-27-21 11:49AM  
07:00AM  
May-19-21 04:05PM  
07:09AM  
May-11-21 12:08PM  
07:30AM  
May-10-21 12:18PM  
07:09AM  
May-09-21 03:40AM  
May-07-21 09:31PM  
06:02AM  
May-06-21 06:50PM  
04:02PM  
02:45PM  
May-04-21 04:01PM  
May-03-21 02:56AM  
Apr-29-21 05:00PM  
Apr-27-21 08:00AM  
Apr-22-21 04:05PM  
Apr-21-21 04:01PM  
Apr-19-21 04:10PM  
Apr-15-21 04:12PM  
Apr-09-21 07:06AM  
Apr-07-21 04:34PM  
03:13PM  
09:34AM  
Apr-06-21 10:41AM  
10:08AM  
09:38AM  
06:40AM  
06:00AM  
Apr-02-21 04:05PM  
Mar-24-21 08:00AM  
Mar-19-21 02:48AM  
Mar-01-21 04:15PM  
04:14PM  
Feb-26-21 11:00AM  
06:00AM  
05:01AM  
Feb-25-21 02:30PM  
Feb-24-21 10:04AM  
Feb-21-21 04:58AM  
Feb-19-21 03:33PM  
12:20PM  
Feb-16-21 04:05PM  
Feb-11-21 04:05PM  
Feb-09-21 08:09AM  
Feb-08-21 04:13PM  
10:11AM  
Feb-04-21 04:05PM  
11:03AM  
08:00AM  
Feb-02-21 03:33PM  
Feb-01-21 11:24PM  
01:15PM  
10:35AM  
07:02AM  
07:01AM  
07:00AM  
Jan-28-21 07:05AM  
Jan-25-21 08:00AM  
Jan-21-21 08:05AM  
Jan-20-21 04:05PM  
Jan-08-21 06:02AM  
Jan-07-21 12:13PM  
08:00AM  
Jan-06-21 04:05PM  
Dec-23-20 08:00AM  
Dec-11-20 11:42AM  
08:11AM  
Dec-10-20 04:05PM  
Dec-04-20 03:00AM  
Nov-17-20 04:05PM  
Nov-16-20 06:00AM  
Nov-10-20 05:33AM  
Nov-07-20 08:58AM  
Nov-06-20 07:33AM  
03:01AM  
Nov-05-20 06:35PM  
04:01PM  
02:45PM  
Nov-03-20 09:56AM  
Nov-02-20 04:05PM  
Oct-30-20 08:14AM  
Oct-29-20 12:35PM  
Oct-27-20 05:50PM  
Oct-22-20 04:05PM  
Oct-21-20 05:50PM  
Oct-19-20 03:30PM  
Oct-13-20 07:09AM  
06:00AM  
Oct-07-20 10:00AM  
Oct-02-20 05:50PM  
Sep-24-20 04:05PM  
Sep-15-20 08:58AM  
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novack David FPresident & COOApr 01Sale9.9220,000198,400117,399Apr 02 06:00 PM
Burgess JustinPrincipal Accounting OfficerMar 02Sale8.821,16510,2757,010Mar 02 07:52 PM
Burgess JustinPrincipal Accounting OfficerMar 01Sale8.882,95826,2678,175Mar 02 07:52 PM
Janssen RobertSenior Vice PresidentFeb 01Sale10.6442,155448,52986,485Feb 03 06:28 PM
Janssen RobertSenior Vice PresidentJul 17Sale11.0950,000554,500127,266Jul 20 07:42 PM